Leiomyosarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LMY004 MIFTS: 58	Leiomyosarcoma Categories: Cancer diseases, Muscle diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Leiomyosarcoma

MalaCards integrated aliases for Leiomyosarcoma:

Name: Leiomyosarcoma ¹² ⁷⁷ ⁵⁴ ⁶⁰ ⁵⁶ ⁶ ⁴⁵ ¹⁵ ¹⁷ ⁷⁴

Leiomyosarcomas ¹² ¹⁵

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Muscle diseases

See all MalaCards categories (disease lists)

ICD10: ³⁵

Neoplasms

Malignant neoplasms of mesothelial and soft tissue

Malignant neoplasm of other connective and soft tissue

Malignant neoplasm: Connective and soft tissue, unspecified

External Ids:

Disease Ontology ¹² DOID:1967

MeSH ⁴⁵ D007890

NCIt ⁵¹ C3158

SNOMED-CT ⁶⁹ 51549004

MESH via Orphanet ⁴⁶ D007890

ICD10 via Orphanet ³⁵ C49.9

UMLS via Orphanet ⁷⁵ C0023269

Orphanet ⁶⁰ ORPHA64720

EFO ¹⁷ EFO_0000564

UMLS ⁷⁴ C0023269

Sources

Summaries for Leiomyosarcoma

NIH Rare Diseases : ⁵⁴ Leiomyosarcoma is a rare cancerous tumor that consists of smooth (involuntary) muscle cells. Leiomyosarcoma is a type of sarcoma. It spreads through the blood stream and can affect the lungs, liver, blood vessels, or any other soft tissue in the body. The exact cause of leiomyosarcoma is not known, although genetic and environmental factors appear to be involved. It is most often found in the uterus or abdomen.

MalaCards based summary : Leiomyosarcoma, also known as leiomyosarcomas, is related to myxoid leiomyosarcoma and cutaneous leiomyosarcoma. An important gene associated with Leiomyosarcoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Phospholipase-C Pathway. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include uterus, liver and breast, and related phenotypes are cellular and behavior/neurological

Disease Ontology : ¹² A smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.

Wikipedia : ⁷⁷ Leiomyosarcoma, is a malignant (cancerous) smooth muscle tumor. A benign tumor originating from the... more...

Sources

Related Diseases for Leiomyosarcoma

Diseases in the Leiomyosarcoma family:

Inflammatory Leiomyosarcoma

Diseases related to Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 518)

#	Related Disease	Score	Top Affiliating Genes
1	myxoid leiomyosarcoma	34.4	ACTC1 PGR
2	cutaneous leiomyosarcoma	33.8	ACTC1 DES FH
3	small intestine leiomyosarcoma	33.6	IGF2 KIT
4	epithelioid leiomyosarcoma	33.5	ACTC1 DES ENO2 SERPINA3 VIM
5	gastric leiomyosarcoma	33.0	ENO2 IGF2 KIT PDGFRA
6	uterine carcinosarcoma	30.5	KIT PGR TP53
7	bizarre leiomyoma	30.5	ACTC1 PGR
8	adenocarcinoma	30.4	CDK4 KIT PDGFRB TP53
9	smooth muscle tumor	30.4	ACTC1 DES KIT PGR VIM
10	sarcoma	30.3	CDK4 KIT MDM2 TP53 VIM WT1
11	sarcoma, synovial	30.3	DES KIT MDM2 VIM
12	fibrous histiocytoma	30.3	ACTC1 DES S100B SERPINA3 VIM
13	hypereosinophilic syndrome	30.3	KIT PDGFRA PDGFRB
14	carcinosarcoma	30.2	ACTC1 DES KIT PGR TP53 VIM
15	pleomorphic lipoma	30.2	MDM2 PGR
16	spindle cell sarcoma	30.2	ACTC1 DES MDM2 S100B VIM
17	liposarcoma	30.1	CDK4 DES MB MDM2 TP53 VIM
18	mesenchymoma	30.1	DES MB MDM2
19	neurofibroma	30.1	KIT PDGFRA S100B
20	gastrointestinal stromal tumor	30.1	ACTC1 DES ENO2 IGF2 KIT PDGFRA
21	giant cell tumor	30.1	ACTC1 DES SERPINA3 VIM
22	histiocytoma	30.1	KIT MB MDM2 SERPINA3 TP53
23	leiomyoma	30.0	ACTC1 DES FH IGF2 KIT PGR
24	endosalpingiosis	30.0	PGR WT1
25	benign breast phyllodes tumor	30.0	KIT PGR VIM
26	malignant giant cell tumor	30.0	ACTC1 S100B TP53
27	myxoid liposarcoma	29.9	CDK4 MDM2 TP53
28	teratoma	29.9	ACTC1 ENO2 KIT TP53
29	syringocystadenoma papilliferum	29.9	ACTC1 DES S100B VIM
30	angiomyoma	29.9	ENO2 KIT MB
31	dedifferentiated liposarcoma	29.8	ACTC1 CDK4 DES MDM2 TP53
32	endometrial cancer	29.8	CDK4 KIT MDM2 PGR TP53
33	glomus tumor	29.7	ACTC1 DES ENO2 TP53 VIM
34	malignant fibroxanthoma	29.7	ACTC1 CDK4 DES MDM2 S100B SERPINA3
35	diffuse peritoneal leiomyomatosis	29.7	KIT PGR WT1
36	desmoid tumor	29.7	KIT PDGFRA PDGFRB
37	neurilemmoma	29.7	DES ENO2 KIT PDGFRA S100B VIM
38	epulis	29.7	DES ENO2 PGR VIM
39	lipomatosis, multiple	29.6	CDK4 DES MDM2
40	endometrial stromal sarcoma	29.6	ACTC1 DES KIT MB PDGFRB PGR
41	pleomorphic adenoma	29.5	ACTC1 MDM2 S100B TP53 VIM
42	cutaneous fibrous histiocytoma	29.5	ACTC1 DES S100B SERPINA3 VIM
43	embryonal rhabdomyosarcoma	29.3	DES IGF2 MB MYOG
44	renal cell carcinoma, nonpapillary	29.3	FH KIT PDGFRB S100A1 VIM WT1
45	uterine sarcoma	29.2	DES KIT MB MDM2 PDGFRB WT1
46	spinal meningioma	29.1	ENO2 IGF2 PGR
47	glioblastoma	29.1	CDK4 MDM2 PDGFRA PDGFRB TP53
48	glioblastoma multiforme	29.1	CDK4 MDM2 PDGFRA PDGFRB TP53
49	meningioma, familial	29.0	ENO2 IGF2 PGR TP53
50	malignant mesenchymoma	28.9	CDK4 DES KIT MB MDM2 MYOG

Graphical network of the top 20 diseases related to Leiomyosarcoma:

Sources

Symptoms & Phenotypes for Leiomyosarcoma

MGI Mouse Phenotypes related to Leiomyosarcoma:

⁴⁷ (show all 21)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.49	ACTC1 CDK4 DES ENO2 FH IGF2
2	behavior/neurological	MP:0005386	10.44	CDK4 DES ENO2 IGF2 KIT MDM2
3	cardiovascular system	MP:0005385	10.44	ACTC1 CDK4 DES IGF2 KIT MB
4	homeostasis/metabolism	MP:0005376	10.44	ACTC1 CDK4 DES FH IGF2 KIT
5	growth/size/body region	MP:0005378	10.35	ACTC1 CAPN6 CDK4 ENO2 IGF2 KIT
6	embryo	MP:0005380	10.34	CDK4 IGF2 KIT MB MDM2 MYOG
7	muscle	MP:0005369	10.34	ACTC1 CAPN6 CDK4 DES IGF2 KIT
8	mortality/aging	MP:0010768	10.33	ACTC1 CDK4 DES FH IGF2 KIT
9	hematopoietic system	MP:0005397	10.26	CDK4 IGF2 KIT MB MDM2 PDGFRA
10	endocrine/exocrine gland	MP:0005379	10.2	CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
11	integument	MP:0010771	10.19	CDK4 IGF2 KIT MDM2 MYOG PDGFRA
12	craniofacial	MP:0005382	10.18	CAPN6 ENO2 IGF2 KIT MDM2 PDGFRA
13	digestive/alimentary	MP:0005381	10.17	CAPN6 CDK4 IGF2 KIT MDM2 PDGFRA
14	normal	MP:0002873	10.1	ACTC1 CDK4 KIT MDM2 MYOG PDGFRA
15	limbs/digits/tail	MP:0005371	10.02	IGF2 KIT MDM2 PDGFRA PDGFRB PGR
16	no phenotypic analysis	MP:0003012	9.97	IGF2 KIT MDM2 MYOG PDGFRA PGR
17	neoplasm	MP:0002006	9.95	CDK4 KIT MDM2 PDGFRA PGR TP53
18	renal/urinary system	MP:0005367	9.81	CDK4 FH IGF2 KIT MDM2 PDGFRA
19	pigmentation	MP:0001186	9.65	CDK4 KIT MDM2 PDGFRA TP53
20	reproductive system	MP:0005389	9.65	CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
21	respiratory system	MP:0005388	9.32	ENO2 IGF2 KIT MB MYOG PDGFRA

Sources

Drugs & Therapeutics for Leiomyosarcoma

Drugs for Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Oxaliplatin

Approved, Investigational

Phase 4,Phase 1

61825-94-3

43805 6857599 5310940 9887054

Liver Extracts

Phase 4,Phase 3,Phase 1,Not Applicable

Cola

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Mechlorethamine

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

51-75-2

4033

Ifosfamide

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

3778-73-2

3690

Doxorubicin

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

23214-92-8

31703

Docetaxel

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

114977-28-5

148124

Gemcitabine

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

95058-81-4

60750

Trabectedin

Approved, Investigational

Phase 3,Phase 2,Phase 1

114899-77-3

108150

Dacarbazine

Approved, Investigational

Phase 3,Phase 2,Phase 1

4342-03-4

5351166

Lenograstim

Approved, Investigational

Phase 3,Phase 2

135968-09-1

Etoposide

Approved

Phase 3,Phase 2

33419-42-0

36462

Carboplatin

Approved

Phase 3,Phase 2

41575-94-4

10339178 38904 498142

Dactinomycin

Approved, Investigational

Phase 3,Phase 2

50-76-0

457193 2019

Vincristine

Approved, Investigational

Phase 3,Phase 2

2068-78-2, 57-22-7

5978

Epirubicin

Approved

Phase 3,Phase 2

56420-45-2

41867

Cyclophosphamide

Approved, Investigational

Phase 3,Phase 2

50-18-0, 6055-19-2

2907

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Ondansetron

Approved

Phase 3

99614-02-5

4595

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3,Phase 2,Not Applicable

50-02-2

5743

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3,Phase 2,Not Applicable

1177-87-3

Bevacizumab

Approved, Investigational

Phase 3,Phase 2

216974-75-3

Sargramostim

Approved, Investigational

Phase 3,Phase 2,Phase 1

123774-72-1, 83869-56-1

Daunorubicin

Approved

Phase 2, Phase 3

20830-81-3

30323

Olaratumab

Approved, Investigational

Phase 3,Phase 1

1024603-93-7

Histamine

Approved, Investigational

Phase 3

51-45-6

774

Cyproheptadine

Approved

Phase 3

129-03-3

2913

Doxil

Approved June 1999

Phase 3,Phase 2,Phase 1,Not Applicable

31703

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

Alkylating Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antineoplastic Agents, Alkylating

Phase 3,Phase 2,Phase 1,Not Applicable

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1,Not Applicable

Isophosphamide mustard

Phase 3,Phase 2,Phase 1,Not Applicable

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable

Antimitotic Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Infective Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antiviral Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1

Pharmaceutical Solutions

Phase 3,Phase 2,Not Applicable

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2

Etoposide phosphate

Phase 3,Phase 2

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2

Antirheumatic Agents

Phase 3,Phase 2,Phase 1

Narcotics

Phase 3

Interventional clinical trials:

(show top 50) (show all 167)

#	Name	Status	NCT ID	Phase	Drugs
1	Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer	Unknown status	NCT00274885	Phase 4	oxaliplatin
2	Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma	Unknown status	NCT01344018	Phase 3
3	Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma	Unknown status	NCT00334854	Phase 3	doxorubicin hydrochloride;ifosfamide
4	A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma	Completed	NCT01692678	Phase 3	Trabectedin;Dacarbazine
5	A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma	Completed	NCT01343277	Phase 3	Trabectedin;Dacarbazine
6	Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma	Completed	NCT00346164	Phase 3	doxorubicin hydrochloride;ifosfamide
7	Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus	Completed	NCT00002459	Phase 3
8	Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma	Completed	NCT00002764	Phase 3	doxorubicin hydrochloride;ifosfamide
9	Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma	Completed	NCT00002641	Phase 3	doxorubicin hydrochloride;ifosfamide;isolated perfusion
10	Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma	Completed	NCT00003212	Phase 3	doxorubicin hydrochloride;ifosfamide
11	Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma	Completed	NCT00003052	Phase 3	doxorubicin hydrochloride;etoposide;ifosfamide
12	Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma	Completed	NCT00061984	Phase 3	doxorubicin hydrochloride;ifosfamide
13	Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis	Completed	NCT00091351	Phase 3
14	Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma	Completed	NCT00423618	Phase 3
15	Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma	Completed	NCT00002898	Phase 3	carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
16	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
17	Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen	Completed	NCT00016380	Phase 3	dexamethasone;ondansetron
18	Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy	Completed	NCT00753688	Phase 3	PAZOPANIB;Placebo
19	A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma	Recruiting	NCT03016819	Phase 3	AL 3818;Dacarbazine
20	Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy	Recruiting	NCT01710176	Phase 3	epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
21	Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery	Active, not recruiting	NCT01533207	Phase 3	Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
22	Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery	Active, not recruiting	NCT02180867	Phase 2, Phase 3	Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
23	A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma	Active, not recruiting	NCT02451943	Phase 3	Olaratumab;Doxorubicin;Placebo
24	Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma	Not yet recruiting	NCT02997358	Phase 3	Doxorubicin;Trabectedin
25	Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma	Terminated	NCT01012297	Phase 3	Docetaxel;Gemcitabine Hydrochloride
26	Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	Terminated	NCT01132547	Phase 3	cyproheptadine hydrochloride
27	Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma	Terminated	NCT01189253	Phase 2, Phase 3	doxorubicin hydrochloride;trabectedin
28	Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin	Withdrawn	NCT03773510	Phase 3	Trabectedin discontinuation;Trabectedin continuation
29	Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -	Unknown status	NCT02203760	Phase 2	Pazopanib plus Gemcitabine;Pazopanib
30	Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas	Unknown status	NCT01442662	Phase 2	pazopanib + gemcitabine
31	Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum	Unknown status	NCT02587169	Phase 1, Phase 2	Nilotinib-adriamycin
32	Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma	Unknown status	NCT00033709	Phase 2	temozolomide;thalidomide
33	Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma	Unknown status	NCT00003718	Phase 2	temozolomide
34	Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma	Unknown status	NCT00410462	Phase 2	brostallicin;doxorubicin hydrochloride
35	Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma	Unknown status	NCT01883518	Phase 1, Phase 2
36	Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma	Completed	NCT02249702	Phase 2	gemcitabine + docetaxel;trabectedin
37	Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma	Completed	NCT02247544	Phase 2	Trabectedin
38	Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma	Completed	NCT02131480	Phase 2	Doxorubicin;Trabectedin
39	Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma	Completed	NCT00856050	Phase 2	letrozole
40	Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma	Completed	NCT02428192	Phase 2
41	Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus	Completed	NCT01637961	Phase 2	Alisertib
42	Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma	Completed	NCT00282087	Phase 2	gemcitabine, docetaxel, doxorubicin
43	Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy	Completed	NCT01220609	Phase 2	Ixabepilone
44	Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus	Completed	NCT00378911	Phase 2	sunitinib malate
45	SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma	Completed	NCT02303262	Phase 2	Mocetinostat;Gemcitabine
46	Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus	Completed	NCT00379145	Phase 2	trabectedin
47	Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma	Completed	NCT00310518	Phase 2	ARQ 501
48	Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma	Completed	NCT00101127	Phase 2	docetaxel;gemcitabine hydrochloride
49	Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma	Completed	NCT00227669	Phase 2	docetaxel;gemcitabine hydrochloride
50	Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma	Completed	NCT00004066	Phase 2	docetaxel;gemcitabine hydrochloride

Search NIH Clinical Center for Leiomyosarcoma

Cochrane evidence based reviews: leiomyosarcoma

Sources

Genetic Tests for Leiomyosarcoma

Sources

Anatomical Context for Leiomyosarcoma

MalaCards organs/tissues related to Leiomyosarcoma:

⁴²

Uterus, Liver, Breast, Smooth Muscle, Lung, Kidney, Bone

Sources

Publications for Leiomyosarcoma

Articles related to Leiomyosarcoma:

(show top 50) (show all 3502)

#	Title	Authors	Year
1	Coexistence of a Basal Cell Carcinoma and Leiomyosarcoma: An Unusual Collision Tumor. ( 31082817 )	G?lseren D...Gru AA	2019
2	Cutaneous leiomyosarcoma: a clinical, dermoscopic, pathologic case study. ( 30932400 )	De Giorgi V...Massi D	2019
3	PGR Gene Fusions Identify a Molecular Subset of Uterine Epithelioid Leiomyosarcoma With Rhabdoid Features. ( 30829727 )	Chiang S...Antonescu CR	2019
4	Hepatic pleomorphic leiomyosarcoma after surgery for gastric gastrointestinal stromal tumor: a case report. ( 30993477 )	Muranushi R...Shirabe K	2019
5	Ileal leiomyosarcoma presenting with intussusception. ( 30800281 )	?tor Z...Han?el J	2019
6	Palisading and Verocay Body Prominent Orbital Leiomyosarcoma, Masquerading as a Schwannoma. ( 30326763 )	Im S...Yoo C	2019
7	Leiomyosarcoma of the Urinary Bladder in Adult Patients: A Systematic Review of the Literature and Meta-Analysis. ( 30384363 )	Zieschang H...Froehner M	2019
8	Tumor regression after combination of radiation and PD-1 antibody nivolumab treatment in a patient with metastatic mediastinal leiomyosarcoma: a case report. ( 30388926 )	Xi C...Ping W	2019
9	Intractable Repeated Intracerebral Hemorrhage Due to Primary Dural Leiomyosarcoma: Case Report and Literature Review. ( 30391601 )	Saito A...Uenohara H	2019
10	Leiomyosarcoma and Pleomorphic Dermal Sarcoma: Guidelines for Diagnosis and Treatment. ( 30409380 )	Llombart B...Sanmart?n O	2019
11	Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors. ( 30489320 )	Arias-Stella JA...Chiang S	2019
12	Incidence and groups at risk for unexpected uterine leiomyosarcoma: a Dutch nationwide cohort study. ( 30498966 )	van den Haak L...Jansen FW	2019
13	A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). ( 30519622 )	Slomovitz BM...Coleman RL	2019
14	Irreversible electroporation in a case of pancreatic leiomyosarcoma: a novel weapon versus a rare malignancy? ( 30611280 )	Papalampros A...Felekouras E	2019
15	A Case of Mediastinal Leiomyosarcoma Demonstrated on FDG PET/CT Imaging. ( 30624267 )	Wu X...Jiang L	2019
16	MRI screening for uterine leiomyosarcoma. ( 30637854 )	Tong A...Hindman N	2019
17	Clinicopathological features of primary thyroid leiomyosarcoma without Epstein-Barr virus infection: A case report. ( 30655765 )	Wei J...Wen Y	2019
18	Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model. ( 30660363 )	Miyake K...Hoffman RM	2019
19	Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition. ( 30683135 )	Fourneaux B...Italiano A	2019
20	Soft tissue leiomyosarcoma-diagnostics, management, and prognosis: Data of the registry cancer of the center of Tunisia. ( 30719261 )	Mestiri S...Mokni M	2019
21	A case of subcutaneous leiomyosarcoma of the scrotum presenting as a slowly growing mass in a 36-year-old male: A case report and literature review. ( 30719409 )	Matsuda-Mitake Y...Takeda M	2019
22	Treatment of leiomyosarcoma in a tiger (Panthera tigris) with stereotactic radiotherapy. ( 30746806 )	Boudreaux BB...Baker DG	2019
23	Synchronous metastatic leiomyosarcoma and primer invasive ductal carcinoma tumors in the same breast: Mammography, ultrasonography, and magnetic resonance imaging findings. ( 30761666 )	Yilmaz R...Dursun M	2019
24	Preoperative intravascular ultrasonographic evaluation of leiomyosarcoma of the inferior vena cava: A case report. ( 30762237 )	Chiba E...Omoto K	2019
25	Polytetrafluoroethylene is a safe and effective interposition conduit for caval reconstruction after resection of primary leiomyosarcoma of the inferior vena cava. ( 30769055 )	Kalluri AG...Eskandari MK	2019
26	Leiomyosarcoma Manifesting With Bowel Obstruction. ( 30772310 )	Bernard L...Hopkins L	2019
27	Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease. ( 30793095 )	Hemming ML...Crompton BD	2019
28	Leiomyosarcoma of the Right Gonadal Vein: Review of the Approach and Prognostic in a Rare Case. ( 30805242 )	de la Fuente N...Artigas V	2019
29	A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. ( 30807865 )	Zhang Z...Hoffman RM	2019
30	Adjuvant Therapy for Early Uterine High-Grade Leiomyosarcoma. ( 30811297 )	Tomao F...Tomao S	2019
31	Unusual presentation of metastatic leiomyosarcoma-right forearm swelling. ( 30834106 )	Wright OW...Chandrasekar C	2019
32	Primary leiomyosarcoma of the thyroid gland with prior malignancy and radiotherapy: A case report and review of literature. ( 30842958 )	Vujosevic S...Sopta J	2019
33	Primary hepatic leiomyosarcoma successfully treated by transcatheter arterial chemoembolization: A case report. ( 30842965 )	Zhu KL...Cai XJ	2019
34	Laparoscopic pancreaticoduodenectomy for remnant pancreatic recurrence after laparoscopic distal pancreatectomy and hepatectomy for greater omentum leiomyosarcoma. ( 30843350 )	Nakagawa Y...Kaneoka Y	2019
35	Longer survival in patients with metastatic uterine leiomyosarcoma treated with trabectedin: A case report. ( 30847179 )	Henry T...Lamuraglia M	2019
36	Presentation of a Rare Malignancy: Leiomyosarcoma of the Prostate. ( 30867634 )	Ermann DA...Silberstein PT	2019
37	Primary leiomyosarcoma of the colon: a case report and review of the literature. ( 30879400 )	Devriendt S...Vanrykel F	2019
38	Autotransplantation of the Liver for Ex Vivo Resection of Intrahepatic Caval Leiomyosarcoma: A Case Report. ( 30880647 )	Buchholz BM...Muiesan P	2019
39	Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage. ( 30881199 )	Patel D...Movva S	2019
40	Promising effects of pazopanib with radiation on an advanced prostate leiomyosarcoma after failure of systemic chemotherapy. ( 30887661 )	Lin MH...Hsiao HH	2019
41	A large soft tissue mass with multiple cysts-Primary leiomyosarcoma of the seminal vesicle. ( 30887718 )	Yu YQ...Liu J	2019
42	Imaging findings of ovarian leiomyosarcoma with histopathologic correlations. ( 30898403 )	Fischetti A...Rollandi GA	2019
43	Bilateral leiomyosarcoma of kidneys with pericardial metastases: a double whammy. ( 30898939 )	Kumar S...Tyagi S	2019
44	Two Modest Proposals: Thoughts from the Myoma/Leiomyosarcoma Controversies. ( 30904485 )	Olive DL	2019
45	Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases. ( 30918878 )	Paik ES...Lee JW	2019
46	Uterine Inversion Presenting as Pelvic Organ Prolapse in a Patient with Leiomyosarcoma. ( 30926367 )	Free L...Wohlrab K	2019
47	Large primary leiomyosarcoma of the seminal vesicle: A case report and literature revision. ( 30932433 )	Corongiu E...Forte F	2019
48	Primary adrenal leiomyosarcoma with inferior vena cava extension in a 70-year-old man. ( 30936336 )	Doppalapudi SK...Bargman V	2019
49	Portal vein leiomyosarcoma: A rare case of hepatic hilar tumor with review of the literature. ( 30950452 )	Gaignard E...Meunier B	2019
50	Recurrent bilateral deep vein thrombosis after cava vein resection in a patient with leiomyosarcoma. ( 30956953 )	Lucia OO...Jorge DT	2019

Sources

Genes for Leiomyosarcoma

Genes related to Leiomyosarcoma (0 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	34.96	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	10086344 14529656 16082245 (more) 12893208 15015617 15196872 16634920 17193824 19537128 17253165 15161707 15622586 15894930 10478672 11865845 12640147 14633453 15796874 20081808 16472759 17049587 15232741 17367465
2	ACTC1	Actin Alpha Cardiac Muscle 1	Protein Coding	33.9	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	14576480 9298873 8872438 (more) 8140724 15382570 18496422 18613884 18941404 9557263 15105807 9500227 15913431 9127317 7778693 9065590 15232741 8203266
3	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	31.36	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	17049587 17316415 19432672
4	MDM2	MDM2 Proto-Oncogene	Protein Coding	29.09	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	8198970 15024701 9159347 (more) 8064888 10412269 9454661 11179833 10606188
5	PGR	Progesterone Receptor	Protein Coding	28.99	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15536333 9299270 18778186 (more) 20437637 9840313 15992918 17550381 9891238 15066464 11567229 14521746 7788328
6	DES	Desmin	Protein Coding	28.67	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	8933907 14576480 2174404 (more) 11759055 10981874 11914617 17253165 8723906 15622586 18496422 11257619 10478672 19432672 17278201 9654192 9557263 9368594 1950562 18941404 15105807 9298873 1752649 15232741 15043462 7778693 16472759 15796874 16033061 18702371 15864383 14521746 1716444 1712542 7520048 18565690 15913431 14633453 11473460 16136754 15382570 8140724 20495760 15702318 12944549 12874903
7	MB	Myoglobin	Protein Coding	28.11	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15084850 16033061
8	FH	Fumarate Hydratase	Protein Coding	27.42	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15949892 12177782 18986479
9	VIM	Vimentin	Protein Coding	27.16	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	1716444 9298873 16136754 (more) 17725305 18613884 1710948 16033061 18702371 15753962 15796874 9654192 15913431 7520048 8620418
10	SERPINA3	Serpin Family A Member 3	Protein Coding	26.48	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
11	CDK4	Cyclin Dependent Kinase 4	Protein Coding	26.08	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15024701
12	ENO2	Enolase 2	Protein Coding	26.03	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	2266593 15056226 8837346 (more) 15232741
13	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	25.72	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15894930 17049587
14	WT1	WT1 Transcription Factor	Protein Coding	25.44	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	19734847 18528287 20025481
15	IGF2	Insulin Like Growth Factor 2	Protein Coding	25.22	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	9184179 1358435 20396563 (more) 12447687 2208134 7981680
16	S100B	S100 Calcium Binding Protein B	Protein Coding	24.92	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15622586 7645984 9298873 (more) 15774214
17	TP53	Tumor Protein P53	Protein Coding	23.73	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	MYOG	Myogenin	Protein Coding	20.61	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	11688574 10227726 11473460
19	CAPN6	Calpain 6	Protein Coding	17.05	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	17291261
20	S100A1	S100 Calcium Binding Protein A1	Protein Coding	16.52	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	18505417 14633453 15796874 (more) 18250540

Sources

Variations for Leiomyosarcoma

ClinVar genetic disease variations for Leiomyosarcoma:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	CHEK2	NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs)	deletion	Conflicting interpretations of pathogenicity	rs555607708	GRCh37	Chromosome 22, 29091857: 29091857
2	CHEK2	NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs)	deletion	Conflicting interpretations of pathogenicity	rs555607708	GRCh38	Chromosome 22, 28695869: 28695869

Cosmic variations for Leiomyosarcoma:

⁹ (show top 50) (show all 687)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location
1	COSM6987318	ZFHX3	soft tissue,smooth muscle,leiomyosarcoma,NS	c.2513A>G	p.N838S	16:72957633-72957633
2	COSM212945	XPO1	soft tissue,smooth muscle,leiomyosarcoma,NS	c.782G>A	p.R261Q	2:61496985-61496985
3	COSM6986268	TSC1	soft tissue,smooth muscle,leiomyosarcoma,NS	c.1079C>A	p.T360N	9:132911064-132911064
4	COSM44683	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.652G>A	p.V218M	17:7674879-7674879
5	COSM10704	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.844C>T	p.R282W	17:7673776-7673776
6	COSM44732	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.512A>G	p.E171G	17:7675100-7675100
7	COSM44327	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.518T>C	p.V173A	17:7675094-7675094
8	COSM43615	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.473G>C	p.R158P	17:7675139-7675139
9	COSM307332	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.976G>A	p.E326K	17:7673552-7673552
10	COSM44057	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.517G>C	p.V173L	17:7675095-7675095
11	COSM1640842	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.641A>C	p.H214P	17:7674890-7674890
12	COSM10790	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.455C>T	p.P152L	17:7675157-7675157
13	COSM11224	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.394A>C	p.K132Q	17:7675218-7675218
14	COSM43878	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.427G>A	p.V143M	17:7675185-7675185
15	COSM10705	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.586C>T	p.R196*	17:7674945-7674945
16	COSM43632	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.493C>T	p.Q165*	17:7675119-7675119
17	COSM10662	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.743G>A	p.R248Q	17:7674220-7674220
18	COSM44238	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.631A>G	p.T211A	17:7674900-7674900
19	COSM10735	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.638G>A	p.R213Q	17:7674893-7674893
20	COSM10667	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.646G>A	p.V216M	17:7674885-7674885
21	COSM43700	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.712T>A	p.C238S	17:7674251-7674251
22	COSM43965	TP53	soft tissue,smooth muscle,leiomyoma,NS	c.734G>C	p.G245A	17:7674229-7674229
23	COSM44610	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.97-2A>T	p.?	17:7676274-7676274
24	COSM43949	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.401T>G	p.F134C	17:7675211-7675211
25	COSM43753	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.560-1G>A	p.?	17:7674972-7674972
26	COSM45135	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.673-1G>T	p.?	17:7674291-7674291
27	COSM13745	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.994-1G>C	p.?	17:7670716-7670716
28	COSM10758	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.659A>G	p.Y220C	17:7674872-7674872
29	COSM10656	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.742C>T	p.R248W	17:7674221-7674221
30	COSM11476	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.452C>A	p.P151H	17:7675160-7675160
31	COSM44537	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.595G>T	p.G199*	17:7674936-7674936
32	COSM10690	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.473G>A	p.R158H	17:7675139-7675139
33	COSM11073	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.1024C>T	p.R342*	17:7670685-7670685
34	COSM10905	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.451C>T	p.P151S	17:7675161-7675161
35	COSM10663	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.916C>T	p.R306*	17:7673704-7673704
36	COSM10768	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.535C>T	p.H179Y	17:7675077-7675077
37	COSM43989	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.596G>A	p.G199E	17:7674935-7674935
38	COSM44415	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.711G>C	p.M237I	17:7674252-7674252
39	COSM21585	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.376-2A>T	p.?	17:7675238-7675238
40	COSM44190	TP53	soft tissue,liver,sarcoma,NS	c.359A>T	p.K120M	17:7676010-7676010
41	COSM10654	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.637C>T	p.R213*	17:7674894-7674894
42	COSM10788	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.764T>G	p.I255S	17:7674199-7674199
43	COSM10726	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.856G>A	p.E286K	17:7673764-7673764
44	COSM43778	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.713G>T	p.C238F	17:7674250-7674250
45	COSM44956	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.808T>G	p.F270V	17:7673812-7673812
46	COSM11658	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.955A>T	p.K319*	17:7673573-7673573
47	COSM44960	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.708C>G	p.Y236*	17:7674255-7674255
48	COSM3849376	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.753C>G	p.I251M	17:7674210-7674210
49	COSM10648	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.524G>A	p.R175H	17:7675088-7675088
50	COSM44567	TP53	soft tissue,smooth muscle,leiomyosarcoma,NS	c.647T>C	p.V216A	17:7674884-7674884

Copy number variations for Leiomyosarcoma from CNVD:

⁷

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	102985	16	58400001	69400000	Loss		Leiomyosarcoma

Sources

Expression for Leiomyosarcoma

Search GEO for disease gene expression data for Leiomyosarcoma.

Sources

Pathways for Leiomyosarcoma

Pathways related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁵ Show member pathways ILK Signaling ⁶⁵ MAPK Signaling ⁶⁵ Molecular Mechanisms of Cancer ⁶⁵ Rho Family GTPases ⁶⁵	13.76	CAPN6 CDK4 DES IGF2 KIT MDM2
2	Phospholipase-C Pathway ⁶⁵ Show member pathways PTEN Pathway ⁶⁵	12.94	IGF2 KIT MDM2 PDGFRA PDGFRB TP53
3	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	12.75	CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
4	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.73	CDK4 KIT MDM2 PDGFRA PDGFRB TP53
5	MAPK signaling pathway ¹ ³⁸	12.65	IGF2 KIT PDGFRA PDGFRB TP53
6	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.64	CDK4 IGF2 KIT PGR TP53
7	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.6	CDK4 MDM2 PDGFRA PDGFRB TP53
8	Downstream signaling events of B Cell Receptor (BCR) ⁶⁷ Show member pathways Activation of RAS in B cells ⁶⁷ Signaling by the B Cell Receptor (BCR) ⁶⁷	12.6	KIT MDM2 PDGFRA PDGFRB TP53
9	MicroRNAs in cancer ³⁸	12.35	MDM2 PDGFRA PDGFRB TP53 VIM
10	Pathways in cancer ³⁸	12.28	CDK4 FH IGF2 KIT MDM2 PDGFRA
11	Human T-cell leukemia virus 1 infection ³⁸	12.26	CDK4 PDGFRA PDGFRB TP53
12	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.22	CAPN6 MDM2 PDGFRA PDGFRB TP53
13	Immune response IFN alpha/beta signaling pathway ²³ Show member pathways Cytokine Network ⁶⁵ Interferon alpha/beta signaling ⁶⁷ Regulation of IFNA signaling ⁶⁷	12.13	IGF2 KIT PDGFRA PDGFRB TP53
14	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁶ Show member pathways Akt Signaling Pathway ⁶⁶	12.02	CDK4 MDM2 PDGFRA PDGFRB TP53
15	AKT Signaling Pathway ⁶⁸	11.87	CDK4 MDM2 PDGFRA PDGFRB TP53
16	Retinoblastoma (RB) in Cancer ¹	11.75	CDK4 MDM2 TP53
17	Neural Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁶	11.69	PDGFRA S100B VIM
18	Bladder cancer ¹ ³⁸	11.65	CDK4 MDM2 TP53
19	Striated Muscle Contraction ¹ ⁶⁷	11.63	ACTC1 DES VIM
20	Integrated Cancer Pathway ¹	11.39	CDK4 MDM2 TP53
21	Central carbon metabolism in cancer ³⁸	11.37	KIT PDGFRA PDGFRB TP53
22	DNA damage_ATM/ATR regulation of G1/S checkpoint ²³	11.36	CDK4 MDM2 TP53
23	Cardiac Progenitor Differentiation ¹	11.18	ACTC1 IGF2 KIT PDGFRA
24	Glioblastoma Multiforme ⁶⁵	11.15	CDK4 IGF2 MDM2 PDGFRA PDGFRB TP53
25	Oncogene Induced Senescence ⁶⁷	11.14	CDK4 MDM2 TP53
26	G-protein signaling_Rap2B regulation pathway ²³	10.87	DES IGF2 KIT PDGFRA PDGFRB VIM

Sources

GO Terms for Leiomyosarcoma

Cellular components related to Leiomyosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:0005737	9.53	ACTC1 CAPN6 CDK4 DES ENO2 FH

Biological processes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of protein kinase B signaling	GO:0051897	9.83	IGF2 KIT PDGFRA PDGFRB
2	positive regulation of gene expression	GO:0010628	9.8	ACTC1 KIT MDM2 TP53 VIM WT1
3	positive regulation of MAPK cascade	GO:0043410	9.78	IGF2 KIT PDGFRA PDGFRB
4	cell chemotaxis	GO:0060326	9.75	KIT PDGFRA PDGFRB
5	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.74	KIT PDGFRA PDGFRB
6	positive regulation of fibroblast proliferation	GO:0048146	9.71	CDK4 PDGFRA PDGFRB
7	muscle filament sliding	GO:0030049	9.67	ACTC1 DES VIM
8	metanephric mesenchyme development	GO:0072075	9.56	PDGFRB WT1
9	retina vasculature development in camera-type eye	GO:0061298	9.55	PDGFRA PDGFRB
10	negative regulation of apoptotic process	GO:0043066	9.55	ACTC1 MDM2 PDGFRB TP53 WT1
11	positive regulation of phosphatidylinositol 3-kinase activity	GO:0043552	9.54	KIT PDGFRA PDGFRB
12	metanephric S-shaped body morphogenesis	GO:0072284	9.51	PDGFRB WT1
13	cellular response to actinomycin D	GO:0072717	9.46	MDM2 TP53
14	metanephric glomerular capillary formation	GO:0072277	9.43	PDGFRA PDGFRB
15	cardiac myofibril assembly	GO:0055003	9.43	ACTC1 PDGFRA PDGFRB
16	positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway	GO:0038091	9.4	PDGFRA PDGFRB
17	positive regulation of cell proliferation	GO:0008284	9.17	CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
18	positive regulation of phospholipase C activity	GO:0010863	9.13	KIT PDGFRA PDGFRB

Molecular functions related to Leiomyosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.5	DES MDM2 PGR S100A1 S100B TP53
2	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.33	KIT PDGFRA PDGFRB
3	platelet-derived growth factor binding	GO:0048407	9.32	PDGFRA PDGFRB
4	vascular endothelial growth factor binding	GO:0038085	8.62	PDGFRA PDGFRB
5	protein binding	GO:0005515	10.19	CDK4 DES ENO2 FH IGF2 KIT

Sources

Sources for Leiomyosarcoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia